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Despite advances in burn treatment and care, infection
remains the main cause of mortality in modern burn units.
In addition to the wound, the respiratory tracts, and the
intestines, the bloodstream is also prone to significant
infection in burn victims [1–3]. However, patients with major
burns usually require intravascular devices, such as central
venous catheters (CVCs) and arterial lines. Unfortunately,
such catheters may increase the risk of bloodstream infec-
tions. Hence, preventing catheter-associated infection would
significantly affect the morbidity of nosocomial infection, the
length of stay, the potential mortality, and the economic costs
for patients with burns [4].
However, unlike other medical or surgical intensive care unit
(ICU) patients, those with major burns cannot be treated with
common practices for preventing central line-associated
bloodstream infection (CLABSI) [5]. In burn units, CVCs are
often located just at or near the wound sites because the normal
skin is limited. Given their proximity to the wound, the
catheters can easily be contaminated. Therefore, the incidence
of CLABSI in patients in the burn ICU is two to three times higher
than that in patients in other ICUs [6]. However, at present, there
are no well-defined guidelines or criteria for catheter-site care in
burn patients, and practices vary widely from one burn unit to
another [7]. To organize protocols for preventing CLABSI in burn
patients, it is essential to analyze the efficacy of different
interventions that may reduce colonization of the catheter site
and prevent bloodstream infection.
In this prospective study, a systematic analysis of the
protective effects of various factors in CVC insertion and care
was conducted in patients with major burns. These factors
included the topical administration of antimicrobials, the
frequency of catheter-site care, the location of the catheters,
and the time of CVC exchange. Thus, we aimed to design burn-
specific protocols to prevent CLABSI and to identify future
areas of improvement.
2. Materials and methods
2.1. Design and population
This study was carried out at the Burn Department of
Southwest Hospital from February to August 2013. The study
was approved by the ethics committee and entered into the
clinical trial registry of the Southwest Hospital, Third Military
Medical University. All adult patients with major burn wounds
admitted to the ICU who were scheduled for CVC cannulation
were eligible for the study. The exclusion criteria were as
follows: (1) preexisting blood infection (positive blood culture
or other signs of infection) prior to CVC insertion, (2) the
application of other topical antibacterial agents (e.g., silver
sulfadiazine) to the skin around the CVC insertion site, (3)
allergy to the skin disinfectant or mupirocin, (4) the use of
CVCs for hemodialysis, and (5) an inability to provide consent.
In addition, patients who received a new catheter as early as 15
days after removal of the first CVC were permitted to enroll
again in the same group.The sample size was determined by a preliminary study on
the decolonization effect of mupirocin on the skin at the CVC
insertion site. In that study, the positive rate of bacterial
colonization was 13.3% versus 33.3% in the mupirocin group
and PVP. When alpha was set at 0.01 and 1  beta at 0.95, the
minimal sample size of the skin swab was 145. Suitable
subjects were assigned alternately into four groups by the
attending nurses, who were blinded to the subsequent
interventions. In each group, the routine daily care of the
CVC exit sites was carried out as follows: (1) disinfection thrice
a day with 0.5% povidone iodine (PVP-I, Sichuan Alex Huatian
Technology Industrial Co., Chengdu, China), combined with
2 g of mupirocin ointment (Bactroban, GlaxoSmithKline,
Tianjing, China); (2) disinfection once a day with 0.5% PVP-I,
combined with 2 g of mupirocin ointment once a day; (3)
disinfection thrice a day with 0.5% PVP-I alone; and (4)
disinfection once a day with 0.5% PVP-I alone.
2.2. Interventions
The same antiseptic solution (0.5% PVP-I) was used for
disinfecting the skin before catheter insertion. Before CVC
insertions, a skin swab sample was collected and colonized for
control. The catheter was inserted using standard aseptic
techniques [8].
After CVC insertion, the exit sites were disinfected with the
assigned solution every day. The groups undergoing antisepsis
thrice daily were disinfected at 9:00, 15:00, and 21:00 h. The
groups with once-daily antisepsis were disinfected at 9:00 h
every day. The disinfection was performed according to a
standard protocol [9]. In detail, skin swabs were collected from
around the insertion site immediately after removing the
dressing, and then from the exit site. A 60 cm2 surrounding
area was disinfected with the corresponding solution, and
finally the CVC exit site was covered with a piece of sterile
gauze.
2.3. Colonization
For the skin samples, after the gauze was removed while
changing the dressing, a sterile moistened cotton applicator
was used to swab the CVC insertion site and a 12 cm2 area of
skin surrounding the site. The swab was then placed in a
sterile tube containing 1.0 mL of 0.01 M phosphate-buffered
saline and immediately transferred to the microbiology
laboratory. For the CVC tips, the catheters were removed
aseptically. The distal 5 cm of the catheters was sectioned
with sterile scissors. The same process was followed for the
skin swab samples.
After vortex mixing and diluting, the samples for the
culture growth screening test were incubated on a Columbia
blood agar base (Difco, Franklin Lakes, NJ, USA) for 24 h at 37 8C
in 5% CO2 in air. To validate the methods of this study,
American Type Culture Collection (ATCC) strains of
Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC
27853), Klebsiella pneumoniae (ATCC 700603), and Staphylococcus
aureus (ATCC 25923) were used as controls in the agar
screening test. The colonies were counted after incubation,
and skin samples with >60 cfu (5 cfu/cm2) or catheter tips with
>15 cfu were considered positive. Isolated bacterial strains
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then identified by their species using the API Vitek 2
automated system (BioMe´rieux, Saint-Vulbas, France) [10].
2.4. Diagnosis of CLABSI
CLABSI was diagnosed according to the definition of the
Centers for Disease Control and Prevention [11]. In detail,
CLABSI was recognized based on the following criteria: (1) the
patient had a recognized pathogen cultured from one or more
blood cultures; (2) the patient had at least fever (>38 8C), chills,
or hypotension, and signs and symptoms and positive
laboratory results not related to an infection at another site;
and (3) a positive culture of the catheter tip (confirming
colonization) with the same microorganism was found in the
blood culture.
Sets of aerobic and anaerobic blood cultures (BacT/Alert FA
and FN, BioMe´rieux) were routinely performed when a patient
had fever (body temperature >38 8C), hypothermia (body
temperature <36.5 8C), chills, hypotension, or other features
of systemic inflammatory response syndrome (SIRS). In
patients clinically suspected of having CLABSI, two or more
peripheral blood samples were collected for culture before or
immediately after catheter removal. In these cases, CVCs were
removed or changed, with routine tip colonization. All
cultures were processed by the clinical microbiology labora-
tory according to the standard methods mentioned earlier.
2.5. Statistical methods
All patient characteristic data are presented as mean  stan-
standard deviation (SD), and statistical analysis was per-
formed using Student’s t-test. The effect of the risk factors
was analyzed by multivariate logistic regression or the chi-
squared test, as appropriate. To quantify the effects, the
relative risk (RR) and 95% confidence interval (CI) were
calculated. The correlation between the skin and catheter
tip colonization results was analyzed by the Pearson
correlation test. Differences of p < 0.05 were considered to
be statistically significant.Fig. 1 – Subject recruitment, exclusion, allocat3. Results
3.1. Comparison of groups
A total of 53 CVCs in 32 patients, for a total of 366 line days,
including 27 CVCs from 17 patients in the mupirocin group and
26 CVCs from 15 patients in the control group, were analyzed.
Of the 53 CVCs, 6 were excluded from tip colonization and
diagnosis of CLABSI for the following reasons: 4 CVCs were
accidentally discarded, and 2 patients were discharged or
transferred before the catheters could be removed (Fig. 1). The
demographic data are summarized in Table 1.
3.2. Microorganism analysis of CVC colonization
A total of 118 strains of pathogenic microorganisms were
isolated from the 187 skin swab samples from the CVC insertion
sites and the 47 CVC tips. On characterizing these isolates, the
most frequent microbial colonizers of the CVC insertion sites
were found to be Acinetobacter baumannii (49.1%), S. aureus
(28.4%), and P. aeruginosa (4.9%) (Fig. 2A). A. baumannii (42.9%), S.
aureus (21.4%), and P. aeruginosa (21.4%) were also the dominant
strains on the catheter tip samples (Fig. 2B). During this study,
only one fungal organism was isolated, and mupirocin-
resistant Staphylococcus was not identified in any of the samples.
3.3. CVC exit-site skin colonization
A total of 187 skin swab samples from the 53 CVC insertion sites
were included in the analysis. Single-factor regression analysis
revealed that the positive rate of skin colonization at the CVC
insertion site could be reduced significantly by the topical
application of mupirocin (RR = 0.316, p = 0.001) or the increased
frequency of skin disinfection at the insertion site (RR = 0.064,
p = 0.008). Placing CVCs on burned skin could markedly raise the
rate of skin colonization compared with normal skin
(RR = 6.740, p < 0.001). Neither the location of the CVC insertion
nor the duration of catheter placement affected the coloniza-
tion result (Table 2).ion, follow-up, and analysis of this study.
Table 1 – Demographic data and characteristics of patients.
Factors Mupirocin + PVP-I PVP-I p-Value
Number of patients 17 15 –
Age (years) 42.313  17.539 47.467  13.828 0.480
Sex (male/female) 16 (16:1) 4 (12:3) 0.228
Burn area (%TBSA) 58.625  28.319% 59.200  24.016% 0.771
Number of CVCs 29 24 –
Duration of catheterization 6.520  4.307 6.952  3.729 0.727
Insertion-site condition (wound/normal) 1.071 (15:14) 1.4 (14:10) 0.630
Location (internal jugular/femoral) 1.231 (16:13) 1.182 (13:11) 0.942
Fig. 2 – Microorganisms isolated from CVC insertion sites and catheter tips. A. baumannii, S. aureus, and P. aeruginosa were
the dominant strains in the colonization of both CVC insertion sites (A) and catheter tips (B).
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topically at the insertion site, subgroup analysis was
conducted indicating that disinfection with a combination
of mupirocin and PVP-I thrice daily could significantly reduce
the colonization of both Gram-positive and Gram-negative
bacteria at the CVC exit site compared with the application of
PVP-I alone (Fig. 3A). However, no difference was found
between the mupirocin group and the single PVP-I group if the
CVC insertion site was disinfected only once a day (Fig. 3B).
Another subgroup analysis showed that the exit-site coloni-
zation of both Gram-positive and Gram-negative bacteria was
dramatically reduced in the mupirocin group compared with
the control group (Fig. 2C). The bacterial colonization of
healthy skin was slightly lower in the mupirocin group,
although not significantly different.
3.4. CVC tip colonization
Of the 47 catheters analyzed for CVC tip colonization, a total
of 12 patients tested positive. The risk factors for positiveTable 2 – Risk factors for bacterial colonization of the skin of C
Factors 
Method Mupirocin + PVP-I PVP-I 
Frequency T.I.D. Q.D. 
Insertion site Wound Normal 
CVC location Internal jugular Femoral 
Duration of catheter 1–15 days catheter tip culture are shown in Table 3. Logistic regression
analysis showed that the rate of positive catheter tips was
significantly affected by the additional topical application of
mupirocin (RR = 0.212, p = 0.040). However, inconsistent with
the skin colonization results, the use of the internal jugular as
the insertion site rather than the femoral vein was observed
to remarkably reduce the rate of positive catheter tips
(RR = 0.214, p = 0.048). Furthermore, the CVC tip colonization
outcomes were moderately correlated with the exit-site skin
colonization results (correlation coefficient = 0.444,
p = 0.002).
3.5. The incidence of CLABSI
In the 47 CVCs with tip colonization results, 6 lines were
diagnosed as CLABSI (12.7% of all lines). The total
incidence of CLABSI was 19.6 per 1000 catheter days. A.
baumannii was the main pathogenic bacteria causing
CLABSI, as it was isolated in five out of six positive blood
culture samples. Five patients with CLABSI were in theVC insertion sites.
RR 95% CI p-Value
0.316 0.061–0.620 0.001
0.604 0.415–0.878 0.008
skin 6.740 3.044–14.919 <0.001
0.981 0.493–1.950 0.965
1.039 0.827–1.306 0.742
Fig. 3 – Subgroup analysis of the decolonization effect of mupirocin at CVC exit-site skin. (A) Skin disinfection with the
combination of mupirocin and PVP-I three times a day (T.I.D.) could reduce the colonization of both Gram-positive
(3.13 W 2.17% vs. 17.24 W 4.96%, p = 0.009) and Gram-negative bacteria (12.50 W 4.13% vs. 44.83 W 6.53%, p < 0.001) at the
insertion site when compared with PVP-I alone. (B) No difference was observed in the positive rates of skin colonization
between the mupirocin group and the control group when skin was disinfected once a day (Q.D.). (C) Topical application of
mupirocin could reduce the colonization of both Gram-positive (5.41% vs. 21.05%, p = 0.046) and Gram-negative (18.92% vs.
60.53%, p < 0.001) bacteria on the CVC exit-site skin when the catheters were placed on the burn wound. (D) No difference
was observed when the CVCs were placed in normal skin.
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incidence of CLABSI was 5.3 per 1000 catheter days in the
mupirocin group, which was significantly lower than that
observed in the PVP-I group (29.1 per 1000 catheter-days,Table 3 – Risk factors for positive CVC tip colonization.
Factors 
Method Mupirocin + PVP-I PVP-I 
Frequency T.I.D. Q.D. 
Insertion site Wound Normal s
CVC location Internal jugular Femoral 
Duration of catheter 1–15 days p < 0.001). However, other factors, such as the insertion-
site care frequency, the CVC location, and the skin
condition at the insertion site, did not significantly affect
the incidence of CLABSI.RR 95% CI p-Value
0.212 0.040–0.870 0.033
0.528 0.211–1.321 0.172
kin 4.499 0.739–27.402 0.103
0.214 0.040–0.943 0.042
1.152 0.944–1.405 0.163
b u r n s 4 1 ( 2 0 1 5 ) 1 8 3 1 – 1 8 3 818364. Discussion
Patients with major burns often require CVCs for intravenous
fluid infusion, blood transfusion, medication administration,
parenteral nutrition, or other therapies because their periph-
eral veins are often damaged or inaccessible. It is occasionally
necessary to insert catheters through or near the wound due to
the extent of the burned skin. In such cases, microorganisms
that enter via catheters are an important source of blood-
stream infection, because burn wounds are usually highly
contaminated and cannot be disinfected as effectively as
normal skin can [12]. Ordinary CVC dressing regimens, such as
transparent or semipermeable dressings, cannot be used to
exudate burn wounds because they could easily be dampened,
loosened, or soiled. Therefore, CVCs are highly vulnerable to
contamination, making catheter-associated infections a cause
for concern in burn units [13].
Based on reports from other burn units, a high rate (19.6%)
of CLABSI was observed in this study. The increased incidence
reported in this study is likely due to the extent of the wounds
of the patients enrolled in this study (>50% total body surface
area (TBSA)) and the method used to determine the relation-
ship between catheters and bloodstream infections. An
expanded burn area is an identified risk factor for CVC-related
infection [14]. Catheter-related bloodstream infection (CRBSI)
should be diagnosed when infection from other sites with the
same pathogen is excluded [15]. For patients with major burns,
the possibility of infection from the wound cannot typically be
ruled out. In this study, all patients with positive CVC tips and
signs of bloodstream infection were classified as having
CLABSI, which usually has a significantly higher rate than
CRBSI [16]. Therefore, the incidence density of the catheter-
associated infection was increased.
Although many measures have been used to prevent
CLABSI, specific guidelines for CVC care in patients with major
burns have not yet been defined. Therefore, in this open-
labeled controlled clinical study, the various risk factors for
CVC-associated infection were subjected to systemic analysis
to reveal areas of improvement for CVC care practices and to
prevent CLABSI in burn units.
Traditionally, the dominant pathogenic microorganisms in
burn units were S. aureus and P. aeruginosa [17,18]. In recent
years, A. baumannii has become the dominant pathogen of
nosocomial infection in an increasing number of burn ICUs
[10,19]. Our study suggests a similar trend, as A. baumannii was
the most frequently isolated microorganism from CVC
insertion sites, CVC tips, and even the blood of patients with
CLABSI. The change in the microorganism spectrum in burn
ICUs suggests that antibiotics should primarily cover Gram-
negative rods when treating patients with major burns.
Although topical prophylaxis with mupirocin in exit-site
care has proven to be effective in reducing catheter-related
infections in patients with CVCs or peritoneal dialysis
cannulas [20,21], topical antimicrobials are usually not
recommended because they may increase the possibility of
fungal infections and drug resistance [22]. However, given the
extremely high rate of CLABSI in burn units, topical applica-
tion of antibiotic ointment or creams at the insertion sites
might be beneficial. Thus, this study evaluates the protectiveeffect of topical mupirocin against CLABSI in patients with
major burns.
Consistent with this prediction, mupirocin could reduce
the colonization rate at both the CVC exit-site skin and the
CVC tips. It also had a strong protective effect against CLABSI.
Although mupirocin is primarily effective against Gram-
positive cocci but not against Gram-negative non-fermenting
rods, the mupirocin group showed reduced colonization of
both Gram-positive and Gram-negative bacteria. However,
considering the changes in the bacterial patterns of burn units,
the effects of other antibiotic creams at the exit site, such as
gentamicin or Polysporin ointment, should be evaluated in
further studies [23].
Further, the subgroup analysis revealed that the decoloni-
zation effect of mupirocin was associated with the frequency
of insertion-site care. Mupirocin had a prominent protective
effect only when insertion-site care was completed three
times a day. The catheter tip culture also showed a similar
trend, although further study with larger sample sizes is
required to confirm this result. Given the severe skin condition
of patients with major burns, ordinary daily insertion-site care
may not able to prevent microorganism colonization. Hence,
increasing the care frequency could be a simple and effective
method of disinfecting the insertion site better. Furthermore,
the protective effect was enhanced when the CVC was placed
in the wound. However, the additional mupirocin did not
show a different decolonization effect from PVP-I when the
CVC was placed in normal skin. Therefore, if the catheter were
placed in normal skin, mupirocin might not be suggested due
to concerns of inducing drug resistance.
Except for the CVC exit-site care, the factors of CVC
insertion also had significant effects on the incidence of
CLABSI [24]. Because the femoral vein insertion sites were
more vulnerable to contamination and were associated with a
higher incidence of bloodstream infection, the femoral vein is
not recommended for CVC cannulization in the guidelines for
preventing catheter-related infections [8,25]. However, the
femoral vein is still often chosen for CVC insertion in most
burn units as an alternative because burns rarely reach this
site [6]. In this study, we confirmed that femoral vein insertion
is a potent risk factor for positive catheter tip cultures,
although it did not increase bacterial colonization of the skin
around the insertion site. Therefore, CVC cannulization at the
femoral vein should be avoided, even in patients with major
burns, if the internal jugular or subclavian area is not injured.
It is clear that the risk of catheter infection is closely
associated with the distance between the insertion site and
the burned area [26]. This study also revealed a significantly
increased level of bacterial colonization of the insertion-site
skin when the CVCs were placed in the burn wound area. The
CVC tip colonization also showed a similar tendency,
indicating that CVCs should not be inserted in or near an
open burn wound if possible.
Line rotation remains controversial in ICU patients. In our
data, the bacterial colonization of both the skin around the
insertion site and the tip of the catheter were not affected by
the duration of the CVCs. The incidence of catheter-related
sepsis is reported to increase markedly only if catheters are
left for longer than 10 days in burn patients [27]. However, on
comparing routine CVC exchange every 3 days with every 4
b u r n s 4 1 ( 2 0 1 5 ) 1 8 3 1 – 1 8 3 8 1837days, King et al. found that an increased rotation frequency
could reduce the incidence of positive catheter cultures [28].
Thus, the advantages of routine rotation of CVCs must be
evaluated further.
However, this study is not a strictly double-blinded
randomized trial, and the sample size was relatively limited.
In addition, the varying ways of administering systemic
antibiotics may also add interference factors that need to be
taken into account. These defects might lead to biases, leading
to inconclusive results. A further study with a larger sample
size and a standard blind method to patient allocation may
provide stronger evidence.
5. Conclusions
A systemic analysis of the effects of CVC insertion-site care on
patients with major burns was conducted in this controlled
clinical trial. The topical application of mupirocin was proven
to be effective in reducing the bacterial colonization at both
the CVC exit skin and the CVC tips, thereby reducing the
incidence of CLABSI. In addition to prophylaxis with topical
mupirocin, improvements in CVC insertion and daily care,
such as increasing the frequency of insertion-site care and not
using the wound base or the femoral vein for cannulization,
were also able to prevent bacterial colonization. However, the
influence of these factors on CLABSI must be evaluated
further. This research may provide data and evidence that can
be used to compile clinical guidelines for effective CLABSI
prevention in patients with major burns.
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